94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
SYSTEMATIC REVIEW article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1499163
This article is part of the Research Topic Non-coding RNAs as Potential Therapeutics and Biomarkers for Human Diseases View all 9 articles
The prognostic value of miR-34 family in ovarian cancer: A systematic review and meta-analysis
Provisionally accepted- Affiliated Hospital of Zunyi Medical University, Zunyi, China
The aim of this study was to evaluate the association between miR-34 family expression and overall survival (OS) and progression-free survival (PFS) in women with ovarian cancer.Methods: Literature searches were conducted using databases such as PubmMed, Cochrane Library, EMBASE, Web of Science, Wanfang, and CNKI to identify studies reporting pooled hazard ratios (HRs) and 95% confidence intervals (CIs) examining the relationship between miR-34 family expression and overall survival (OS) or progression-free survival (PFS) in female patients with ovarian cancer. All potentially relevant studies were assessed and then pooled.Results: There were a total of seven literatures included in this systematic review and meta-analysis, which included 672 women. There was a significant improvement in survival for women with ovarian cancer when miR-34s expression was higher (OS, HR = 0.70, 95% CI:0.57-0.86; PFS, HR = 0.48, 95% CI:0.31-0.75). A subgroup analysis of miR-34 family members showed that differences between groups greatly affected PFS (HR = 0.50, 95% CI: 0.40-0.63).Based on the results of this review, it appears that ovarian cancer women with high expression of miR-34s may have a better chance of surviving .
Keywords: Meta-analysis, microRNA, MiR-34s, ovarian cancer, prognosis
Received: 25 Sep 2024; Accepted: 28 Feb 2025.
Copyright: © 2025 Luo, Li, Chen and Zheng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiulan Luo, Affiliated Hospital of Zunyi Medical University, Zunyi, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.